New combo therapy aims to tame rare liver disease

NCT ID NCT06755151

Recruiting now Disease control Sponsor: Xijing Hospital of Digestive Diseases Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This long-term study is testing whether adding fenofibrate to standard ursodeoxycholic acid is safe for people with primary biliary cholangitis (PBC), a rare liver disease. About 300 adults who have already completed a prior fenofibrate study will take the combination and be monitored for side effects and liver health. The goal is to see if this combo can be used safely over many years to control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fenofibrate and ursodeoxycholic acid
What this could lead to: If successful, this could provide a safe long-term combination therapy to better control primary biliary cholangitis and reduce liver damage.
What could go wrong: This is an open-label study with no placebo group, so results may be less reliable. Side effects from fenofibrate, such as muscle pain or liver issues, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BILIARY CHOLANGITIS (PBC)

Contacts and locations

Locations

Xijing hospital
RECRUITING

Xi'an, Shaanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.